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Severity of Diabetes Mellitus and Total Hip
or Knee Replacement
A Population-Based Case–Control Study
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Arief Lalmohamed, PhD, Anthonius de Boer, PhD, Bart J.F. van den Bemt, PhD, and Frank de Vries, PhD
Abstract: It is generally thought that people with diabetes mellitus
(DM) are more likely to suffer from osteoarthritis (OA) due to an
increased body mass index (BMI), resulting in mechanical destruction
of cartilage. However, previous studies have suggested a coexisting
metabolic causality.
To evaluate the risk of hip or knee replacement, as a proxy for severe
OA, in patients with DM. We additionally evaluated the risk of total
joint replacement (TJR) with various proxies for increased DM severity.
A population-based case–control study was performed, using the
Clinical Practice Research Datalink (CPRD). Cases (n¼ 94,609) were
defined as patients >18 years who had undergone TJR between 2000
and 2012. Controls were matched by age, gender, and general practice.
Conditional logistic regression was used to estimate the risk of total
knee (TKR) and total hip replacement (THR) surgery associated with
use of antidiabetic drugs (ADs). We additionally stratified current AD
users by proxies for DM severity.
Current AD use was significantly associated with a lower risk of
TKR (OR¼ 0.86 (95% CI¼ 0.78–0.94)) and THR (OR¼ 0.90 (95%
CI¼ 0.82–0.99)) compared to patients not using ADs. Moreover, risk of
TKR and THR was decreased with increasing HbA1c.
This study does not support the theory that DM patients are more
likely to suffer from severe OA as compared to patients without
diabetes. Moreover, risk of severe OA necessitating TJR decreases
with increasing DM severity. This is possibly due to dissimilarities in
methodology, a decrease in eligibility for surgery, or variability of OA
phenotypes.
(Medicine 95(20):e3739)
Abbreviations: AD = antidiabetic drug, AGEs = advanced
glycation end products, BMI = body mass index, CI = confidence
interval, CPRD = Clinical Practice Research Datalink, DM =
diabetes mellitus, DPP = dipeptidyl peptidase, GLP = glucagon-
like peptide, GLUT = glucose transporter, GP = general
practitioner, GPRD = General Practice Research Database,
HbA1c = glycated hemoglobin, ISAC = Independent Scientific
Advisory Committee, KL = Kellgren–Lawrence, OA =
osteoarthritis, OR = odds ratio, QOF = Quality and Outcomes
Framework, RA = rheumatoid arthritis, ROS = reactive oxygen
species, T1DM = type 1 diabetes mellitus, T2DM = type 2 diabetes
mellitus, THR = total hip replacement, TJR = total joint
replacement, TKR = total knee replacement, TZD =
thiazolidinedione, UK = United Kingdom.
INTRODUCTION
O steoarthritis (OA) is the most common cause of pain anddisability in the United Kingdom (UK).1 Approximately
one-third of people aged 45 and over in the UK sought treatment
for pain associated with OA.1 Furthermore, between 1990 and
2010, disability due to OA has increased by 15%.2 In patients
with severe OA, total knee (TKR) and hip (THR) replacement
are considered to improve the quality of life considerably.3
Patients with OA are more likely to suffer from diabetes
mellitus (DM). DM is characterized by several metabolic
problems, such as impaired glucose metabolism and obesity.
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Until recently one of the mechanisms underlying OA was
considered to be an increased mechanical load on the
weight-bearing joints, especially the knee, of these patients.
Previous studies have shown that DM is an independent risk
factor for the nonweight-bearing types of OA, suggesting a
metabolic causality.4–7 In a cross-sectional study of 202 sub-
jects, patients with DM had an increased risk of hand or knee
OA compared to patients without DM (OR 2.18 (95% CI, 1.12–
4.24)).4 Furthermore, a population-based cohort study with a
20-year follow-up in a random sample of 927 subjects showed
an increased risk of total joint replacement (TJR) in type 2 DM
patients compared to non-DM subjects (OR 2.1 (95% CI, 1.1–
3.8)).6 According to the Ulm osteoarthritis study, bilateral hip
and knee OA was more prevalent, although not statistically
significantly, in patients with DM than in patients without DM
(OR 2.21 (95% CI, 0.77–6.41)).7 Despite this, other studies
show no association between OA and DM.8,9
From a biopathological point of view, there is an increas-
ing body of evidence suggesting that hyperglycemia and
advanced glycation end products (AGEs) play an important
role in the progression of OA.10–12 An in vitro study using
chondrocytes, isolated from human cartilage, has concluded
that OA chondrocytes exposed to high levels of glucose were
unable to downregulate glucose transporter-1 (GLUT-1). The
inability to down regulate GLUT-1 resulted in the accumulation
of glucose and the production of reactive oxygen species (ROS),
known for their deleterious effects in various celtypes.10
Furthermore, AGEs have been linked to increased cartilage
stiffness and a reduced capacity to repair articular cartilage.11,12
These factors may be part of the mechanism promoting degen-
erative changes in the cartilage possibly facilitating the pro-
gression of OA.
Hyperglycemia and increased levels of AGEs are likely to
be found in diabetic patients. Particularly poorly controlled or
severe diabetic patients may be subjected to these risk factors
regularly. It is therefore expected that these patients in particular
are more likely to develop, or have a more severe course of OA.
Subsequent progression of OA may in time lead to pain, which
in severe cases can be alleviated by elective joint replacement
surgery.
To date, a limited number of studies assessed the risk of
OA in DM patients and showed inconsistent results. Moreover,
to the best of our knowledge, none of these studies have
determined the risk of OA needing TJR with increasing DM
severity. The aim of this study was to evaluate the risk of TJR
surgery with indicators of the severity of DM. Based on in vitro,
in vivo, and clinical studies we hypothesize that DM could be
associated with an increased risk of OA. Furthermore, we
expect to find a higher risk of OA with increased severity
of DM.
METHODS
This study protocol was approved by the Independent
Scientific Advisory Committee (ISAC), protocol number:
14_054R.
Data Source
We performed a case–control study using the Clinical
Practice Research Datalink (CPRD), previously known as the
General Practice Research Database (GPRD). The CPRD is a
large primary care database containing computerized medical
records registered by over 625 general practitioners (GP) in the
UK, thereby representing over 8% of the British population.
This database provides information on a wide range of medical
records, including diagnoses, prescriptions, referrals, and
laboratory test results. We also used linked data on socio-
economic status from the Index of Multiple Deprivation for
descriptive purposes.
Study Population
All patients aged 18 years or older who had undergone a
primary THR or TKR surgery from January 2000 until the 31st
of October 2012 were selected as cases. Patients with a diag-
nosis of rheumatoid arthritis (RA) or hip/knee fractures pre-
ceding the TJR surgery were excluded from analyses. All cases
were matched to one control patient without a record for TJR
using incidence density sampling. Cases and controls were
matched by year of birth, sex, and general practice. The index
date for the patients was the date of TJR surgery. This date was
imputed for the matched control patient. A patient that did not
undergo TJR before and at the index date of a case, but was still
at risk of undergoing TJR, was matched to this specific case.
Exposure
In order to evaluate the risk between TJR surgery and DM,
we determined the most recent diagnosis of Type 1 DM (T1DM)
or Type 2 DM (T2DM) before the index date. If type of DMwas
not specified these patients were categorized as ‘‘DM type
unspecified.’’ In addition, we determined the recency of
exposure to antidiabetic drugs (ADs): biguanides, sulfonylur-
eas, glitazones, dipeptidyl peptidase-4 (DPP-4) inhibitors, glu-
cagon-like peptide-1 (GLP-1) analogs, glinides, and insulins,
before the index date by reviewing prescriptions. Current users
of these drugs comprised all patients with at least 1 recorded
prescription within the 90-day period before the index date.
Recent users were those with at least 1 prescription within the
180-day period before the index date, but who had stopped using
these drugs 90 days before the index date. Past users were
patients who had stopped using ADs more than 180 days before
the index date.
Proxy indicators for the severity of DM were then defined
using clinical information, lab test values, and exposure to drugs:
Clinical proxies of disease severity included a history of neuro-
pathy or retinopathy 5 years before the index date and renal
function. In addition, lab tests values includingHbA1cand fasting
glucosewere alsoused todetermine the riskofTJRwith increased
severity of DM. HbA1c was stratified into the following groups:
<6.5%, 6.5% to 7.9%, 8% to 9.4%, 9.5%. Fasting plasma
glucosewas stratified into the following groups:<6mmol/L, 6 to
7.4mmol/L, 7.5 to 8.9mmol/L, 9.0mmol/L. The most recent
lab test value in the year before index date was used in this proxy.
Lastly, we used proxy indicators of disease severity using longi-
tudinal information ondrugexposure according to themethodsby
Bazelier et al.13 This was done by stratification of current AD
users, into four treatment stages ranging from mild (Stage 1) to
severe (Stage 4): Stage 1 diabetics were current users of either a
biguanide or a sulfonylurea. Stage 2 diabetics comprised all
patients who used these drugs simultaneously. Stage 3 diabetics
used one or more drugs from the following classes: thiazolidi-
nediones (TZD), GLP-1 analogs, DPP-4 inhibitors, or glinides,
but were not on insulin treatment. Stage 4 diabetics were current
users of insulin.
Covariates
We reviewed the literature to identify potential confoun-
ders for OA and TJR surgery. Factors including age, sex,
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socioeconomic status, body mass index (BMI), and smoking
status were used as potential confounders.14–16 A history of
diseases such as angina pectoris, acute myocardial infarction
(AMI), heart failure, hemorrhagic stroke, ischemic stroke,
cerebrovascular diseases, dementia, arrhythmia, peripheral vas-
cular diseases, ulcers, and nonhip/femur fractures in the
previous year were also included as potential confounders.
Use of statins, loop diuretics, thiazides, NSAIDs, calcium
channel blockers, beta-blockers, RAAS inhibitors, systemic
glucocorticoids in the previous 6 months.17 In all analyses
potential confounders were included if they independently
changed the beta-coefficient for a DM diagnosis or current
AD exposure by at least 5%, or when consensus about inclusion
existed within the team of researchers, supported by clinical
evidence from literature.
Statistical Analysis
Conditional logistic regression analysis was used to esti-
mate the risk of TKR and THR surgery associated with a
diagnosis of DM, and clinical proxies of disease severity
(SAS version 9.3, PHREG procedure). In the analyses, risk
was expressed as odds ratios (OR) with corresponding 95%
confidence intervals (CI). Furthermore, we estimated the risk of
TKR and THR surgery associated with use of ADs. We
additionally stratified current AD users by lab test and drug
use proxies for disease severity. Missing data were classified as
a separate category. Analyses assessing the association between
prespecified treatment stages and HbA1c levels have been
conducted in order to determine whether these treatment stages
reflect DM severity properly. These analyses have been con-
ducted in a set of TKR and THR control patients using an AD.
RESULTS
Baseline characteristics of TKR (n¼ 44,768), THR
patients (n¼ 49,841), and their matched control subjects
(n¼ 94,609) are presented in Table 1. On average, the subjects
were approximately 70 years of age and more than 55% of them
were female. In general, TKR cases were more likely to have a
DM diagnosis (n¼ 5118) compared to TKR controls
(n¼ 4325). TKR cases were particularly more often diagnosed
with T2DM compared to controls. In contrast, THR cases were
less likely to have a DM diagnosis (n¼ 4075) compared to
controls (n¼ 4591), regardless of type. On average, HbA1c
values were lower in the cases compared to the controls in both
TKR and THR subjects. The use of ADs was higher in the TKR
cases compared to their controls. This was in contrast with the
THR cases, where the use of ADs was lower compared to the
controls. Socio-economic status and mean fasting glucose
values were similar in cases and controls in both patient groups.
Mean BMI, however, was higher in cases compared to their
matched controls, especially in the TKR group.
The risk of TJR surgery was 13% to 15% reduced in
patients with a diagnosis of DM versus nondiabetic patients,
with an OR of 0.85 (95% CI, 0.77–0.94) for TKR surgery and of
0.87 (95% CI, 0.82–0.93) for THR surgery. Risk reductions
were on average more pronounced in patients with T1DM for
TKR (OR 0.73; 95% CI, 0.55–0.96) but not for THR (OR 0.89;
95% CI, 0.72–1.11) surgery, as compared with non-DM
patients. In T2DM patients the risk of TKR surgery (OR
0.85; 95% CI, 0.76–0.94) and THR surgery (OR 0.88; 95%
CI, 0.83–0.94) was slightly decreased compared to non-DM
patients. Clinical proxies of the severity of DM were mostly not
associated with risk of TJR. A diagnosis of retinopathy in the
5 years before TKR yielded an OR of 1.37 (95% CI, 0.76–2.49)
and an OR of 2.18 (95% CI, 1.33–3.57) for THR surgery
compared to patients without diabetes. We found no differences
in risk of surgery in patients with a diagnosis of neuropathy in
the 5 years before TKR or THR. Risk of TKR was increased in
patients with a combined diagnosis of retinopathy and a neuro-
pathy in the 5 years before surgery (OR 2.20; 95% CI, 1.04–
4.66), whereas no difference in risk of THR was found (OR
1.29; 95% CI, 0.64–2.57). Deterioration of renal function
(eGFR 30–59 ml/min/1.73 m2) was associated with a reduced
risk of TKR and THR, yielding an OR of 0.69 (95% CI, 0.60–
0.79) and an OR of 0.79 (95% CI, 0.71–0.87) respectively
(Table 2).
The associations between current AD use and risk of TJR
showed similar patterns as compared to the associations
between diagnosis of DM and risk of TJR. Current AD use
was significantly associated with a lower risk of TKR
(OR¼ 0.86 (95% CI, 0.78–0.94)) and THR (OR¼ 0.90 (95%
CI, 0.81–0.99)) compared to patients not using ADs. Moreover,
risk of TKR and THR was decreased with increasing HbA1c in
current AD users as compared to nonusers. More specifically,
both TKR and THR patients using ADs with HbA1c values
<6.5% were at equal risk of surgery as compared to nondiabetic
patients, but patients using ADs with HbA1c 6.5 were at a
lower risk of TJR. TKR (OR¼ 0.53 (95% CI, 0.42–0.66)) and
THR (OR¼ 0.44 (95% CI, 0.34–0.56)) patients with HbA1c
values >9.5% were approximately 50% less likely to undergo
surgery. In contrast, fasting glucose levels were not associated
with a change in risk of TJR. Lastly, treatment stages of current
AD use were generally not associated with risk of surgery.
However, patients using both a biguanide and a sulfonylurea
(stage 2) were less likely to undergo surgery as compared to
nondiabetic patients, with an OR of 0.75 (95% CI, 0.65–0.88)
for TKR surgery and an OR of 0.80 (95% CI, 0.69–0.93) for
THR surgery (Table 3).
The proportion of control subjects currently using an AD
with HbA1c levels 9.5% increases with every step up accord-
ing to the prespecified treatment stages (Table 4). The pro-
portion of subjects with HbA1c levels <6.5% decreases with
every step up.
The inverse association between DM and TJR was no
longer present when taking into account the average Hb1Ac
level in the previous 5 years instead of the single most recent
HbA1c level (Supplementary Table 1, http://links.lww.com/
MD/A987, Supplementary Table 2, http://links.lww.com/MD/
A987). However, risk of TKR and THR was still decreased with
increasing HbA1c levels in current AD users as compared
to nonusers.
DISCUSSION
In contrast to our hypothesis, the present population-based
case–control study did not show a positive association between
various proxy indicators of the severity of DM and the risk of
TJR surgery. On the contrary, we found 13% to 15% reduced
risks between a diagnosis of DM and TJR surgery, and up to a
46% reduction with clinical proxy indicators of disease severity
of DM. The use of ADs was associated with a decreased risk of
TKR (OR¼ 0.86 (95% CI, 0.78–0.94)) and THR (OR¼ 0.90
(95% CI, 0.81–0.99)). Moreover, increasing DM severity,
according to HbA1c levels, was associated with a lower risk
of undergoing TJR surgery. In fact, patients with HbA1c values
>9.5% were approximately 50% less likely to undergo surgery.
When taking into account the average Hb1Ac level in the
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TABLE 1. Baseline Characteristics of TJR Cases and Controls
TKR, n¼ 89,536 THR, n¼ 99,682
Cases (%),
n¼ 44,768
Controls (%),
n¼ 44,768
Cases (%),
n¼ 49,841
Controls (%),
n¼ 49,841
Females 24,912 (55.6) 24,912 (55.6) 29,724 (59.6) 29,724 (59.6)
Age at index date (years, (SD)) 69.5 (9.5) 69.5 (9.5) 68.8 (11.5) 68.8 (11.5)
BMI, most recent before index
date (kg/m2, mean (SD))
29.7 (5.2) 27.0 (5.1) 27.6 (5.0) 26.8 (5.0)
DM diagnosis, most recent diagnosis before index date
DM regardless of type 5118 (11.4) 4325 (10.3) 4075 (8.2) 4591 (9.2)
Type I 149 (0.3) 211 (0.5) 189 (0.4) 243 (0.5)
Type II 4636 (10.4) 4077 (9.1) 3579 (7.2) 3979 (8.0)
Type unspecified 333 (0.7) 307 (0.7) 307 (0.6) 369 (0.7)
History of comorbidity 5 years before index date
Retinopathy 884 (2.0) 911 (2.0) 643 (1.3) 850 (1.7)
Neuropathy 551 (1.2) 441 (1.0) 499 (1.0) 428 (0.9)
eGFR (ml/min/1.73 m2, mean (SD)) 71.9 (17.9) 70.8 (17.9) 71.9 (18.9) 70.4 (18.1)
HbA1c most recent within the year before index date
HbA1c (%, mean (SD)) 6.9 (1.2) 7.1 (1.4) 6.8 (1.2) 7.2 (1.4)
<6.5% 1811 (4.0) 1422 (3.2) 1629 (3.3) 1406 (2.8)
6.5–7.9% 2331 (5.2) 1976 (4.4) 1623 (3.3) 1837 (3.7)
8–9.4% 542 (1.2) 586 (1.3) 411 (0.8) 550 (1.1)
9.5 189 (0.4) 299 (0.7) 133 (0.3) 310 (0.6)
Missing 39,895 (89.1) 40,485 (90.4) 46045 (92.4) 45,738 (91.8)
Fasting glucose most recent within the year before index date
Fasting glucose (mean (SD)) 5.7 (1.5) 5.7 (1.7) 5.6 (1.4) 5.7 (1.7)
<6 mmol/L 3791 (8.5) 3143 (7.0) 3351 (6.7) 3016 (6.1)
6–7.5 mmol/L 818 (1.8) 613 (1.4) 580 (1.2) 590 (1.2)
7.5–8.9 mmol/L 248 (0.6) 152 (0.3) 122 (0.2) 167 (0.3)
9.0 mmol/L 156 (0.3) 149 (0.3) 145 (0.3) 164 (0.3)
Missing 39,755 (88.8) 40,711 (90.9) 45,643 (91.6) 45,904 (92.1)
History of drug use within 6 months before primary TJR surgery
All NIAD 3430 (7.7) 3075 (6.9) 2511 (5.0) 3037 (6.1)
Biguanides 2780 (6.2) 2406 (5.4) 1995 (4.0) 2388 (4.8)
Sulfonylureas 1497 (3.3) 1573 (3.5) 1206 (2.4) 1568 (3.1)
Thiazolidinediones 540 (1.2) 428 (1.0) 311 (0.6) 420 (0.8)
Glinides 38 (0.1) 28 (0.1) 18 (0.0) 26 (0.1)
GLP-1 agonists 53 (0.1) 28 (0.1) 27 (0.1) 17 (0.0)
DPP-4 inhibitors 93 (0.2) 89 (0.2) 62 (0.1) 60 (0.1)
Insulins 747 (1.7) 825 (1.8) 580 (1.2) 837 (1.7)
No. of GP consultations in the year before index date (mean (SD)) 41.3 (25.7) 28.9 (26.2) 40.2 (27.0) 28.0 (26.1)
Socioeconomic status
Low 6945 (15.5) 7120 (15.9) 8248 (16.5) 8054 (16.2)
Low–medium 7176 (16.0) 7011 (15.7) 8200 (16.5) 8015 (16.1)
Medium 5763 (12.9) 5626 (12.6) 6287 (12.6) 6113 (12.3)
Medium–high 4533 (10.1) 4451 (9.9) 4521 (9.1) 4741 (9.5)
High 3077 (6.9) 3240 (7.2) 2896 (5.8) 3191 (6.4)
Missing 17,274 (38.6) 17,320 (38.7) 19,689 (39.5) 19,727 (39.6)
History of comorbidities ever before index date
Angina pectoris 4615 (10.3) 4309 (9.6) 4273 (8.6) 4603 (9.2)
AMI 1929 (4.3) 2336 (5.2) 2139 (4.3) 2308 (4.6)
Ischemic stroke 332 (0.7) 468 (1.0) 347 (0.7) 483 (1.0)
Hemorrhagic stroke 191 (0.4) 261 (0.6) 239 (0.5) 275 (0.6)
Valve disorders 482 (1.1) 587 (1.3) 611 (1.2) 609 (1.2)
Peripheral vascular disorders 550 (1.2) 778 (1.7) 664 (1.3) 764 (1.5)
Ulcers 3280 (7.3) 2441 (5.5) 3250 (6.5) 2815 (5.6)
Nonhip/femur fractures in the year before index date 559 (1.2) 623 (1.4) 957 (1.9) 696 (1.4)
AMI¼ acute myocardial infarction, BMI¼ body mass index, DM¼ diabetes mellitus, DPP-4¼ dipeptidyl peptidase-4, GLP-1¼ glucagon-like
peptide-1, GP¼ general practitioner, HbA1c¼ glycated hemoglobin, NIAD¼ noninsulin antidiabetic drug, SD¼ standard deviation, THR¼ total hip
replacement, TJR¼ total joint replacement, TKR¼ total knee replacement.
Nielen et al Medicine  Volume 95, Number 20, May 2016
4 | www.md-journal.com Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
previous 5 years instead of the single most recent HbA1c level,
the inverse association between DM and TJR was no longer
present. However, risk of TKR and THR was still decreased
with increasing HbA1c levels in current AD users as compared
to nonusers. Although this is probably the first study that
evaluates the associations between DM as well as proxy
indicators for DM severity with the risk of OA-related TJR
surgery, it is not in line with previous studies that evaluated the
association between (severity of) DM and OA.4,6,7 This may be
explained by mechanistic and methodological reasons.
A lacking differentiation of clinical phenotypes may
explain the inverse association between AD use and OA.
Previous work has suggested a division of the disease into
5 distinguishable clinical phenotypes.18 First, a posttraumatic
phenotype has been proposed. This phenotype is mainly caused
by mechanical stress. Second, a metabolic phenotype, caused by
mechanical stress, adipokines, hyperglycemia, and hormonal
imbalance, has been suggested. Third, the aging phenotype
associated with AGEs and chondrocyte senescence has been
mentioned. Fourth, a genetic phenotype has been proposed.
TABLE 2. Risk of Total Knee Replacement (TKR) and Total Hip Replacement (THR) in Current Antidiabetic Drug (AD) Users
Compared With Controls by Clinical Proxies of the Severity of DM
TKR, n¼ (89,536) THR, n¼ (99,682)
DM Status
Case,
n¼ 44,768
Control,
n¼ 44,768
Crude
OR
(95% CI)
Fully
Adjusted OR
(95% CI)
 Case,
n¼ 49,841
Control,
n¼ 49,841
Crude OR
(95% CI)
Fully
Adjusted
OR (95% CI)y
No 39,650 40,173 Ref Ref 45,766 45,250 Ref Ref
Yes 5118 4595 1.13
(1.08–1.18)
0.85 (0.77–0.94) 4075 4591 0.87
(0.84–0.91)
0.87
(0.82–0.93)
By type of DM
Type 1 149 211 0.71
(0.58–0.88)
0.73
(0.55–0.96)
189 243 0.77
(0.64–0.93)
0.89
(0.72–1.11)
Type 2 4636 4077 1.16
(1.10–1.21)
0.85
(0.76–0.94)
3579 3979 0.89
(0.85–0.93)
0.88
(0.83–0.94)
Type unspecified 333 307 1.10 (0.94–1.29) 0.89
(0.73–1.08)
307 369 0.82
(0.71–0.96)
0.79
(0.66–0.94)
By clinical proxies
for DM severity
No neuropathy
or retinopathy
4088 3588 1.16
(1.10–1.21)
0.85
(0.77–0.94)
3317 3669 0.89
(0.85–0.94)
0.86
(0.81–0.92)
Neuropathy only 169 142 1.21
(0.97–1.51)
0.79
(0.56–1.11)
146 144 1.00
(0.80–1.26)
0.88
(0.64–1.22)
Retinopathy only 789 820 0.97 (0.88–1.08) 1.37
(0.76–2.49)
578 721 0.79
(0.70–0.88)
2.18
(1.33–3.57)
Retinopathy
and neuropathy
72 45 1.60
(1.11–2.33)
2.20
(1.04–4.66)
34 57 0.58
(0.38–0.89)
1.29
(0.64–2.57)
By renal function (eGFR)
90 ml/min/1.73 m2 787 568 1.42
(1.27–1.58)
1.11
(0.94–1.30)
624 553 1.12
(1.00–1.26)
1.14
(0.99–1.30)
60–89 ml/min/1.73 m2 2602 2212 1.20
(1.13–1.27)
0.87
(0.77–0.98)
1901 2135 0.88
(0.82–0.94)
0.90
(0.83–0.97)
30–59 ml/min/1.73 m2 1298 1376 0.95
(0.88–1.03)
0.69
(0.60–0.79)
1092 1322 0.81
(0.75–0.88)
0.79
(0.71–0.87)
15–29 ml/min/1.73 m2 51 96 0.54
(0.38–0.75)
0.43
(0.29–0.65)
63 88 0.70
(0.51–0.97)
0.75
(0.52–1.07)
<15 ml/min/1.73 m2 5 23 0.22
(0.08–0.59)
0.26
(0.08–0.78)
12 23 0.51
(0.25–1.03)
0.56
(0.27–1.19)
eGFR missing 375 320 1.18
(1.02–1.38)
0.95
(0.79–1.14)
383 470 0.80
(0.70–0.92)
0.78
(0.66–0.92)
AD¼ antidiabetic drug, CI¼ confidence interval, DM¼ diabetes mellitus, OR¼ odds ratio, THR¼ total hip replacement, TKR¼ total knee
replacement.
Adjusted for smoking status and BMI. Drug use in previous 6 months: statins, thiazides, calcium channel blockers, beta-blockers, RAAS inhibitors,
loop diuretics, nonselective NSAIDs, COX2-selective NSAIDs. History of comorbidity ever before: acute myocardial infarction, heart failure,
cerebrovascular events, ulcers, and peripheral vascular disorders. Retinopathy or neuropathy in 5 years before index date. Most recent value in
previous year for HbA1c and fasting glucose. Stratified variables were excluded as confounder in the analyses stratified by that variable.
yAdjusted for smoking status and BMI. Drug use in previous 6 months: statins, thiazides, calcium channel blockers, beta-blockers, RAAS inhibitors,
loop diuretics, nonselective NSAIDs, COX2-selective NSAIDs. Retinopathy and neuropathy in 5 years before index date. Most recent value in
previous year for fasting glucose. Stratified variables were excluded as confounder in the analyses stratified by that variable.
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Fifth, a pain related phenotype may also exist. According to this
classification, if corrected for overweight, DM may primarily be
associated with metabolic OA, whereas other phenotypes have
other causative features. In this study such a differentiation has
not been made. We have, therefore, not exclusively included
metabolic OA patients. This may explain the fact that we did not
find an increased risk of TJR in DM patients compared to non-
DM patients.
Dissimilarities in methodology, such as the definition of
OA, between studies may be of interest. Other studies have
determined OA by using the American College of Rheumatol-
ogy classification criteria or by using radiographically deter-
mined Kellgren–Lawrence (KL) scores.4,7 In this study we used
TJR surgery to define severe OA. This may not reflect severity
of OA as directly as KL scores, for example, but in epidemiol-
ogy it has been widely used in studies assessing risk factors for
severe OA.6,19 Remarkably, a study using a definition for severe
OA similar to ours reports an increased risk of OA in DM
patients compared to patients without DM.6 Still, several dis-
similarities exist between our study and that by Schett and
colleagues. First, their population demographics, such as mean
age and sex distribution, were different compared to those in our
study. On average the population included by Schett and
colleagues was younger than the patients in our study. A study
by King et al20 reported increased rates of TJR at lower age.
Therefore, this difference may have led to effect modification
by age. After stratification by age we also found a decreased risk
of surgery with increasing age.
It might be possible that, by missing out on the low risk
older population, the analysis by Schett and colleagues resulted
in an overall higher risk of surgery. Second, Schett and col-
leagues adjusted for age, sex, lifestyle factors, cholesterol and
BMI, but no consideration was given toward covariates associ-
ated with hypertension. Since hypertension has also been
considered to be an important component of the metabolic
syndrome, possibly associated with metabolic OA, correction
for this comorbidity is recommended.21 However, when we
estimated ORs without correcting for the use of antihyperten-
sives similar ORs were found compared to analyses with
adjustment for use of antihypertensives (TKR OR¼ 0.86
(95% CI, 0.81–0.91); THR OR¼ 0.90 (95% CI, 0.84–0.95)).
Although evidence is limited, a combination of these methodo-
logical differences may have resulted in our deviating finding.
Although analyses were adjusted for BMI, drug use, and
several comorbidities, other factors may have caused the
inverse association between DM severity and the risk of OA.
First, we should consider confounding by indication. Patients
with DM, especially those with severe DM, are possibly less
eligible for surgery due to an increased risk of surgical com-
plications. For example, the risk of infection associated with
surgery is higher in DM patients compared to patients who do
not have DM.22 More specifically, high HbA1c levels have been
associated with more complications following TJR.23,24 High
HbA1c levels are particularly associated with more surgical site
infections.25 Furthermore, HbA1c levels have been associated
with increased mortality rates in nonorthopedic surgical pro-
cedures.26 Based on these increased risks surgeons may be less
tempted to operate on these patients. Also, patients with DM
could have complications sufficiently serious to prevent
surgery, regardless of risk. The duration of DM may also be
of concern. Clinically, it is difficult to determine start of DM,
therefore time since first AD prescription may be used to
approximate this. Furthermore, DM is known to be underdiag-
nosed and undertreated.27 Therefore, we assessed the risk of TJR
with a DM diagnosis (Table 2) and with the use of an AD
(Table 3). Second, high HbA1c levels are associated with a
decreased adherence to medication.28 The lack of adherence
may suggest care evasive behavior in general and, consequently,
these patients may not be likely to visit their GPs and other
healthcare providers on a regular basis. They are, therefore, less
likely to undergo elective TJR. A combination of these factors
may have resulted in a decreased risk of TJR in patients with
increasing severity of DM compared to patients without DM.
Our study has several strengths. First, it was conducted
using the world’s largest primary care database representative
for the British population and consequently, we were able to
assess the risk in a large population of >90,000 TJR patients.
Second, to our knowledge this is the first study that stratifies risk
of OA by disease severity, based on HbA1c values. Third, we
had detailed information on both patients and their matched
controls. Fourth, medical data were routinely recorded by GPs
without the presence of a study hypothesis, minimizing the
possibility of recall bias. Like most observational studies, our
study is not without limitations. Despite attempts to adjust for
several confounders, causal interpretation of the findings will be
restricted and residual confounding must be considered when
interpreting the results. Furthermore, this study has focused on
severe OA patients, other associations may be found in less
severe subjects. The quality of proxies of disease severity may
also be of concern. HbA1c levels were generally well registered
TABLE 4. Proportion of HbA1c Categories in Controls (No TJR)
Treatment Stages
HbA1c <6.5%,
n¼ (%)
HbA1c 6.5–7.9%,
n¼ (%)
HbA1c 8–9.4%,
n¼ (%) HbA1c 9.5%, n¼ (%)
Stage 1: current use of biguanide
or sulfonylureas only
612 (26.6) 1343 (58.4) 231 (10.0) 115 (5.0)
Stage 2: current use of biguanide and
sulfonylureas, but no use of other ADs
194 (16.8) 618 (53.5) 244 (21.1) 99 (8.6)
Stage 3: current use of TZD, GLP-1 analogs,
DPP-4 inhibitors or glinides
134 (16.2) 449 (54.3) 150 (18.1) 94 (11.4)
Stage 4: current use of insulin 84 (6.7) 480 (38.1) 432 (34.3) 265 (21.0)
Current users of ADs are stratified by treatment stages.
AD¼ antidiabetic drug, DPP-4¼ dipeptidylpeptidase-4, GLP-1¼ glucagon-like peptide-1, HbA1c¼ glycated hemoglobin, TJR¼ total joint
replacement, TZD¼ thiazolidinedione.
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in the diabetic population analyzed in this study (83–88%),
most likely due to the introduction of the Quality and Outcomes
Framework (QOF) indicators for DM in 2004. The impact of
missing data on HbA1c in the diabetes population was therefore
probably of minor concern. Fasting glucose levels, however, are
not included as one of the QOF indicators and consequently
have lower registration rates (13–15%). Based on distribution
of patients according to HbA1c levels, one might suggest that
registration of fasting glucose is predominantly lacking in the
lower fasting glucose categories (<6.0 mmol/L, 6.0–7.4 mmol/
L, and 7.5–8.9 mmol/L). Considering the ORs calculated for the
‘‘fasting glucose missing’’ group, full registration of this test
would probably lead in a reduction of risk in these severity
categories. Misclassification of exposure may also be of con-
cern. Use of ADs is based on prescription data registered in the
CPRD. However, adherence is likely to be <100%. We may
have therefore overestimated the number of patients using ADs.
Assuming this is a nondifferential misclassification, and the
number of AD users would in fact be lower, this would have
resulted in a dilution of the true effect. Consequently, this does
not explain the inverse association presented in this study.
Finally, TJR could be considered to be an inadequate definition
for OA. However, in epidemiology it has been used in previous
studies assessing risk factors for severe OA.6,19 With this
definition we are limited to severe cases of OA, missing
possible beneficial effects in earlier stages of OA.
In conclusion, in contrast to previous reports, the present
study does not indicate that patients with DM are more likely to
suffer from severe OA as compared to nonusers. In fact, the risk
of severe OA necessitating TJR even decreases with increasing
DM severity, based on HbA1c values. This unexpected result
may be caused by variability of OA phenotypes, dissimilarities
in methodology, or a decrease in eligibility for surgery. Our
results suggest more uniform work is still needed to determine
the risk of OA in DM patients. Further research may also
include differentiation of OA into relevant clinical phenotypes.
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